Glaukos EBIT Margin 2014-2025 | GKOS

Glaukos ebit margin for the quarter ending June 30, 2025 was -22.63%.

  • Glaukos average ebit margin for 2024 was -37.51%, a 9.33% decline from 2023.
  • Glaukos average ebit margin for 2023 was -41.37%, a 142.07% decline from 2022.
  • Glaukos average ebit margin for 2022 was -17.09%, a 4.74% increase from 2021.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Glaukos EBIT Margin 2014-2025 | GKOS

  • Glaukos average ebit margin for 2024 was -37.51%, a 9.33% decline from 2023.
  • Glaukos average ebit margin for 2023 was -41.37%, a 142.07% decline from 2022.
  • Glaukos average ebit margin for 2022 was -17.09%, a 4.74% increase from 2021.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$188.8B
Intuitive Surgical (ISRG)$170.7B
IDEXX Laboratories (IDXX)$51.6B
Edwards Lifesciences (EW)$48B
Alcon (ALC)$40.5B
IQVIA Holdings (IQV)$32.5B
DexCom (DXCM)$32.3B
Mettler-Toledo (MTD)$27.2B
STERIS (STE)$24.8B
Waters (WAT)$18B
SONOVA HOLDING (SONVY)$17.3B
Hologic (HOLX)$15.2B
Penumbra (PEN)$10.3B
Globus Medical (GMED)$8.4B
Sysmex ADR (SSMXY)$8.4B
Masimo (MASI)$8.1B
Teleflex (TFX)$5.7B
TransMedics (TMDX)$4.1B
Integer Holdings (ITGR)$3.9B
LivaNova (LIVN)$3.1B
Veracyte (VCYT)$2.4B
Alphatec Holdings (ATEC)$2.4B
PROCEPT BioRobotics (PRCT)$2.3B
Artivion (AORT)$2.1B
Elekta AB (EKTAY)$1.9B
Nihon Kohden (NHNKY)$1.9B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.1B
OPKO Health (OPK)$1.1B
Paragon 28 (FNA)$1.1B